Kura Oncology, Inc. - Bathi saben saham sajrone rolas wulan pungkasan KURA

Simbol resmi perusahaan Kura Oncology (KURA)

High R&D costs and stringent FDA oversight create significant barriers to entry for Kura Oncology, Inc. (KURA). The TTM net income per share reflects business dynamics amid a fierce struggle with pharma behemoths for leadership in targeted therapy, while the value of -3.31 captures the metric level. Operational stability is ensured by strict adherence to regulations during the transportation of biological substances.

KURA Bathi resik saben siji saham sajrone rolas wulan pungkasan Kura (04.07.2022 - 18.11.2026)

Ringkesan rincian data analitis Kura Oncology, Inc. (KURA)

- kuotasi saiki lan rata-rata prakiraan nilai:
Analisis kabeh metrik perusahaan:KURA - Kura Oncology
Produk seri Kura

Trailing twelve-month net earnings per share measures the portion of total income attributable to a single security, allowing for an assessment of real business efficiency without accounting for capital dilution. By analyzing the change in per-share profit over the last 12 months on GURU.Markets, an investor sees the current value of -3.31, which in the case of Kura Oncology, Inc. (KURA) depends critically on the trial results of oncology inhibitors.